Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type A thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. It may be associated with myasthenia gravis and pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II or stage III tumors. The overall survival is reported to be 80-100% at 5 and 10 years.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for thymoma type AB.
3 publications have been identified in PubMed for thymoma type AB. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Epidemiology / Natural History (33%).
Fan R (2025). [PMID: 40578983](https://pubmed.ncbi.nlm.nih.gov/40578983/). *In vivo (Athens, Greece)*. [Case Report / Case Series]
Suster DI (2025). [PMID: 40666531](https://pubmed.ncbi.nlm.nih.gov/40666531/). *Mediastinum (Hong Kong, China)*. [Review / Meta-Analysis]
Yin Y (2024). [PMID: 39533067](https://pubmed.ncbi.nlm.nih.gov/39533067/). *Scientific reports*. [Epidemiology / Natural History]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center